Start your trial — RocSite Caliper

Trial application

Full name *

Job title *

Work email *

Institutional email required (no gmail / yahoo / hotmail / personal addresses).

Organization name *

Organization type *

Use case *

A short description helps us route your application appropriately.

LinkedIn URL (optional, helps verify identity)

Team members (optional, up to 4 additional)

Each gets their own access key under the same trial. Add work emails only.

By submitting, you acknowledge:

30-day evaluation period at no charge
Caliper v0 runs on public adverse-event data only — no PHI, no credentialed data, no private uploads
Findings are hypothesis-generating, not causal claims, and are exploratory unless promoted to audit-grade after operator review
Aggregate methodology validation data may be used per terms
Cryptographic verification keys are public at /keys/

I have read and accept the Caliper Trial Terms. I understand my uploaded data is processed under these terms, not under a separate confidentiality agreement, and that Findings generated from my Uploaded Data become the property of RocSite. For confidential engagements, I will contact [email protected] before uploading data.

What you get during the trial

25 claim validations + 5 discover scans / 30 daysSubmit a drug+AE pair to validate, or just a drug to auto-enumerate the top 20 adverse events
Up to 5 team membersOne access token per person, audit-logged separately
Signed verdicts + audit packetsEvery finding ships as a downloadable signed tar.gz with manifest, bundle, fragment, and verify instructions
Browser-verifiable signaturesAnyone — no login — can confirm the Ed25519 signature against the public key at /keys/
Methodology transparencyPer-finding pre-reg sha1, PRR with 95% CI, Yates χ², co-exposure profile, suspect-drug cohort size
Public ledger chainEvery verdict — positive or null — appends to a chained, signed ledger

Who this is for

Real-world evidence teams, pharmacoepidemiology groups, signal-detection scientists, clinical-pharmacology directors, biotech R&D teams, regulatory-affairs groups.

Not for clinicians making bedside decisions. Findings are hypothesis-generating, not causal claims, and are exploratory unless promoted to audit-grade after operator review.

Questions

Email [email protected] directly.